These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 26692561)
21. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells. Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383 [TBL] [Abstract][Full Text] [Related]
22. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors. Shirai F; Tsumura T; Yashiroda Y; Yuki H; Niwa H; Sato S; Chikada T; Koda Y; Washizuka K; Yoshimoto N; Abe M; Onuki T; Mazaki Y; Hirama C; Fukami T; Watanabe H; Honma T; Umehara T; Shirouzu M; Okue M; Kano Y; Watanabe T; Kitamura K; Shitara E; Muramatsu Y; Yoshida H; Mizutani A; Seimiya H; Yoshida M; Koyama H J Med Chem; 2019 Apr; 62(7):3407-3427. PubMed ID: 30883102 [TBL] [Abstract][Full Text] [Related]
23. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes. Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443 [TBL] [Abstract][Full Text] [Related]
24. Discovery of a Novel Triazolopyridine Derivative as a Tankyrase Inhibitor. Ryu H; Nam KY; Kim HJ; Song JY; Hwang SG; Kim JS; Kim J; Ahn J Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298950 [TBL] [Abstract][Full Text] [Related]
25. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. Chen M; Mashima T; Oishi T; Muramatsu Y; Seto Y; Takamatsu M; Kawata N; Morino S; Nakamura A; Inaba S; Yuan X; Maruyama K; Suzuki M; Sato A; Yoshida H; Jang MK; Mizutani A; Takeuchi K; Yamaguchi K; Shirai F; Nagayama S; Katayama R; Seimiya H Br J Cancer; 2024 Jan; 130(1):151-162. PubMed ID: 37968472 [TBL] [Abstract][Full Text] [Related]
26. Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models. Buchstaller HP; Anlauf U; Dorsch D; Kögler S; Kuhn D; Lehmann M; Leuthner B; Lodholz S; Musil D; Radtki D; Rettig C; Ritzert C; Rohdich F; Schneider R; Wegener A; Weigt S; Wilkinson K; Esdar C J Med Chem; 2021 Jul; 64(14):10371-10392. PubMed ID: 34255518 [TBL] [Abstract][Full Text] [Related]
27. para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors. Haikarainen T; Koivunen J; Narwal M; Venkannagari H; Obaji E; Joensuu P; Pihlajaniemi T; Lehtiö L ChemMedChem; 2013 Dec; 8(12):1978-85. PubMed ID: 24130191 [TBL] [Abstract][Full Text] [Related]
28. Tankyrase is necessary for canonical Wnt signaling during kidney development. Karner CM; Merkel CE; Dodge M; Ma Z; Lu J; Chen C; Lum L; Carroll TJ Dev Dyn; 2010 Jul; 239(7):2014-23. PubMed ID: 20549720 [TBL] [Abstract][Full Text] [Related]
29. PI3K and tankyrase inhibitors as therapeutic targets in colorectal cancer. Yakkala PA; Naaz F; Shafi S; Kamal A Expert Opin Ther Targets; 2024 Mar; 28(3):159-177. PubMed ID: 38497299 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of tankyrase by a novel small molecule significantly attenuates prostate cancer cell proliferation. Cheng H; Li X; Wang C; Chen Y; Li S; Tan J; Tan B; He Y Cancer Lett; 2019 Feb; 443():80-90. PubMed ID: 30472184 [TBL] [Abstract][Full Text] [Related]
31. Structural basis and selectivity of tankyrase inhibition by a Wnt signaling inhibitor WIKI4. Haikarainen T; Venkannagari H; Narwal M; Obaji E; Lee HW; Nkizinkiko Y; Lehtiö L PLoS One; 2013; 8(6):e65404. PubMed ID: 23762361 [TBL] [Abstract][Full Text] [Related]
32. Development and structural analysis of adenosine site binding tankyrase inhibitors. Haikarainen T; Waaler J; Ignatev A; Nkizinkiko Y; Venkannagari H; Obaji E; Krauss S; Lehtiö L Bioorg Med Chem Lett; 2016 Jan; 26(2):328-333. PubMed ID: 26706174 [TBL] [Abstract][Full Text] [Related]
33. The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models. Brinch SA; Amundsen-Isaksen E; Espada S; Hammarström C; Aizenshtadt A; Olsen PA; Holmen L; Høyem M; Scholz H; Grødeland G; Sowa ST; Galera-Prat A; Lehtiö L; Meerts IATM; Leenders RGG; Wegert A; Krauss S; Waaler J Cancer Res Commun; 2022 Apr; 2(4):233-245. PubMed ID: 36873622 [TBL] [Abstract][Full Text] [Related]
34. Biochemical Analysis of Tankyrase Activity in Zebrafish In Vitro and In Vivo. Moon J; Amatruda JF Methods Mol Biol; 2016; 1481():95-100. PubMed ID: 27590155 [TBL] [Abstract][Full Text] [Related]
35. Tankyrase inhibition sensitizes cells to CDK4 blockade. Foronda M; Tarumoto Y; Schatoff EM; Leach BI; Diaz BJ; Zimmerman J; Goswami S; Shusterman M; Vakoc CR; Dow LE PLoS One; 2019; 14(12):e0226645. PubMed ID: 31891587 [TBL] [Abstract][Full Text] [Related]
36. OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors. Ye GD; Sun GB; Jiao P; Chen C; Liu QF; Huang XL; Zhang R; Cai WY; Li SN; Wu JF; Liu YJ; Wu RS; Xie YY; Chan EC; Liou YC; Li BA Gastroenterology; 2016 Mar; 150(3):659-671.e16. PubMed ID: 26619963 [TBL] [Abstract][Full Text] [Related]
37. Interaction of tankyrase and peroxiredoxin II is indispensable for the survival of colorectal cancer cells. Kang DH; Lee DJ; Lee S; Lee SY; Jun Y; Kim Y; Kim Y; Lee JS; Lee DK; Lee S; Jho EH; Yu DY; Kang SW Nat Commun; 2017 Jun; 8(1):40. PubMed ID: 28659575 [TBL] [Abstract][Full Text] [Related]
38. Modulation of stemness in a human normal intestinal epithelial crypt cell line by activation of the WNT signaling pathway. Guezguez A; Paré F; Benoit YD; Basora N; Beaulieu JF Exp Cell Res; 2014 Apr; 322(2):355-64. PubMed ID: 24534551 [TBL] [Abstract][Full Text] [Related]